Target- |
MechanismImmunologic cytotoxicity [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of pancreatic cancer.
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of non-small cell lung cancer.
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of colorectal cancer.
100 Clinical Results associated with Shenzhen Hanke Bioengineering Co., Ltd.
0 Patents (Medical) associated with Shenzhen Hanke Bioengineering Co., Ltd.
100 Deals associated with Shenzhen Hanke Bioengineering Co., Ltd.
100 Translational Medicine associated with Shenzhen Hanke Bioengineering Co., Ltd.